ライフサイエンスコーパス: -mismatched

1 for human leukocyte antigen (HLA)-A/-B/-DR 0-mismatched (0MM) kidneys, we analyzed the results of 264

2 0.77, P=0.05; IL-2RA:0.81, P=0.11) in HLA 0-mismatched recipients.

3 outcomes in human leukocyte antigen (HLA) 0-mismatched deceased donor kidney recipients.

4 In a fully H-2-mismatched, nonlymphopenic, immunocompetent mouse islet

5 2 is a 3' --> 5' exonuclease that removes 3'-mismatched sequences in a biochemical assay; however, it

6 hed duplex vs ODN(CF3-(Ph)ImdC), while for A-mismatched duplex, only a 2-fold decrease was observed.

7 LDLT and ABO-mismatched transplantation constitute feasible options t

8 LDLT, including ABO-mismatched transplantation, constitutes a safe and effic

9 e of an HLA-mismatched donor and a major ABO-mismatched donor.

10 Using a minor histocompatibility Ag-mismatched BMT (B6 --> B6 x C3H.SW) followed by adoptive

11 MHC-matched but minor histocompatibility Ag-mismatched models driven by CD4 T cells.

12 ly responsible for the rejection of minor Ag-mismatched grafts has not yet been identified.

13 med bone marrow transplantations between age-mismatched donor and recipient mice to test the influenc

14 Instead, using age-mismatched nerve transplants in vivo, we show that the e

15 come in patients undergoing HLA-matched and -mismatched allo HCT for MDS.

16 human leukocyte antigen two DR-matched and -mismatched healthy volunteers and prekidney transplant d

17 ultiple clinically relevant MHC-matched and -mismatched murine models of GVHD, we investigated the ro

18 both human leukocyte antigen DR-matched and -mismatched pairs, particularly at therapeutic levels (>/

19 Graft survival of KIR-ligand-matched and -mismatched transplants was compared.

20 which adopts a novel differential and angle-mismatched polarizing optical design achieving wide-fiel

21 Use of 1-antigen-mismatched donors was associated with reduced OS and EFS

22 Older patients and recipients of 1-antigen-mismatched grafts had a less favorable outcome.

23 ng phenotypically HLA-identical or 1-antigen-mismatched relatives (related donors [RDs]).

24 unrelated donor (MUD, n = 152) or 1-antigen-mismatched unrelated adult donor (MMUD, n = 52) or 4-6/6

25 MHC-matched minor histocompatibility antigen-mismatched (mHA-mismatched) and fully MHC-mismatched mod

26 HC-matched, minor histocompatibility antigen-mismatched allogeneic chimeras with CML-like leukemia, i

27 ed multiple minor histocompatibility antigen-mismatched alloHCT using bone marrow (BM) cells and sple

28 In both a minor histocompatibility antigen-mismatched as well as a MHC-haploidentical model of scle

29 or multiple minor histocompatibility antigen-mismatched hematopoietic cell preparation.

30 n patients receiving human leukocyte antigen-mismatched combined kidney and bone marrow transplantati

31 Fifteen human leukocyte antigen-mismatched living donor renal transplant recipients unde

32 co-cultures between human leukocyte antigen-mismatched peripheral blood lymphocytes from healthy adu

33 received CKBMT from human leukocyte antigen-mismatched, haploidentical living-related donors after m

34 mice also delayed rejection of major antigen-mismatched skin and MHC class II-mismatched cardiac allo

35 Unexpectedly, only minor antigen-mismatched grafts were rejected at the same time points

36 zed with CM before receiving a minor antigen-mismatched heart transplant exhibited potent DTH, T-cell

37 vant and received heterotopic, minor antigen-mismatched heart transplants.

38 ulted in prolonged survival of minor antigen-mismatched skin grafts.

39 ystem in which MHC-matched but minor antigen-mismatched tissue (skin) grafts were transplanted into M

40 were not detected only in the minor antigen-mismatched transplantation.

41 ntibody was used in a multiple minor antigen-mismatched, BALB.B (H-2B) to C57BL/6 (H-2B), cardiac all

42 tion, which is MHC-matched but minor antigen-mismatched.

43 iently lysed antigen-matched but not antigen-mismatched targets 5 years after vaccination.

44 Single antigen-mismatched mouse model (C57BL/6 RIP-GP in C57BL/6) was u

45 of an RPBA cutoff with RPBA data) and assay-mismatched cutoffs (e.g., with the use of microbiologic

46 The application of assay-mismatched cutoffs leads to a misinterpretation of folat

47 ciency for assay-matched compared with assay-mismatched cutoffs were 35% compared with 56% (serum fol

48 ciency for assay-matched compared with assay-mismatched cutoffs were 5.6% compared with 16% (serum fo

49 The preferred HLA-B-mismatched donor is leader-matched and shares a T leader

50 3%) HLA-matched and 1457 (4.3%) single HLA-B-mismatched transplantations using multivariate regressio

51 Among the single HLA-B-mismatched transplantations, acute GVHD risk was higher

52 e HLA-B leader informs GVHD risk after HLA-B-mismatched unrelated HCT and differentiates high-risk HL

53 of the leader dimorphism in GVHD after HLA-B-mismatched unrelated HCT.

54 nfluenza B ICU patients received influenza B-mismatched trivalent vaccine.

55 rget miRNA-21 from its single- and four-base-mismatched counterparts and another non-complementary mi

56 rence between the target and the single-base-mismatched DNA, resulting in a differential signal that

57 lack criteria for donor selection when HLA-C-mismatched donors are a patient's only option for cure.

58 -host disease (GVHD) limits the use of HLA-C-mismatched unrelated donors in transplantation.

59 -C allotype in 1975 patients and their HLA-C-mismatched unrelated transplant donors.

60 VE against clade-mismatched B(Yamagata) viruses was 42% (95% CI, 10% to 6

61 r partial calendar-time adjustment for clade-mismatched B/Wisconsin/01/2010-like virus (VE, 63%; 95%

62 using minor major histocompatibility complex-mismatched B6.C-H2 donor hearts in C57BL/6(H-2) recipien

63 rafted into major histocompatibility complex-mismatched BALB/c mice.

64 ations from major histocompatibility complex-mismatched donors.

65 el of fully major histocompatibility complex-mismatched ectopic heart transplants.

66 Fully major histocompatibility complex-mismatched heterotopic heart transplantation (BALB/c to

67 ntly, fully major histocompatibility complex-mismatched islets were transplanted into naive diabetic

68 ontext of a major histocompatibility complex-mismatched liver transplant and in the context of liver

69 Using the major histocompatibility complex-mismatched mouse orthotopic lung transplant model, we in

70 ngent fully major histocompatibility complex-mismatched murine skin allograft model to study graft su

71 plants, and major histocompatibility complex-mismatched porcine peripheral blood mononuclear cell.

72 ocytes were major histocompatibility complex-mismatched to the recipients (n = 3).

73 njection of major histocompatibility complex-mismatched UTC did not induce a detectable immune respon

74 o the fully major histocompatibility complex-mismatched WF rat recipients.

75 rs to fully major histocompatibility complex-mismatched Wistar Furth rat or C57 mouse recipients with

76 ing a fully major histocompatibility complex-mismatched, life-sustaining, murine model of renal allog

77 ur data demonstrate that GVHD after HLA-DPB1-mismatched CD4+ DLI can be mediated by allo-reactive HLA

78 4+ DLI after 10/10-HLA-matched, but HLA-DPB1-mismatched TCD-alloSCT.

79 Among recipients of HLA-DPB1-mismatched transplants from donors with the low-expressi

80 er when the recipient and donor are HLA-DPB1-mismatched, but the mechanisms leading to GVHD are unkno

81 Lewis rats received full-mismatched Brown Norway rat hindlimb transplants.

82 emic potential increases yearly when a group-mismatched HA subtype dominates seasonal influenza circu

83 D-related outcomes were higher in HLA-DP GVH-mismatched unrelated recipients than in HLA-matched sibl

84 potent antileukemic activity following haplo-mismatched, T cell-depleted stem cell transplantations f

85 Major histocompatibility-mismatched ACI (RT1) donors and Wistar Furth (WF) (RT1)

86 ection of major and minor histocompatibility-mismatched allografts performed in large-animal models r

87 ound that human and minor histocompatibility-mismatched donor mouse heart allografts with alloimmune-

88 t from MHC-matched, minor histocompatibility-mismatched donors; recipients of plerixafor mobilized pe

89 anting MHC-matched, minor histocompatibility-mismatched grafts composed of purified HSCs, HSCs plus b

90 loped a single human leukocyte antigen (HLA)-mismatched heterotopic murine heart transplant model (HL

91 nts, partially human leukocyte antigen (HLA)-mismatched, or HLA-haploidentical, related donor bone ma

92 rejection of Human Leukocyte Antigens (HLA)-mismatched induced pluripotent stem cells (iPSCs) limits

93 HLA-mismatched unrelated donor (MMUD) hematopoietic stem-cel

94 Fifty-seven HLA-matched donors, 12 HLA-mismatched donors, and 1 CD3(+)TCR alphabeta/CD19 deplet

95 ecipients, including 125 cord blood, 125 HLA-mismatched, and 154 HLA-matched HCTs, detection of multi

96 unique peripheral blood samples from 348 HLA-mismatched renal transplant recipients and 101 nontransp

97 (n = 1), HLA-matched unrelated (n = 9), HLA-mismatched unrelated (n = 3), and HLA haploidentical sib

98 replete grafts, 97% received marrow, 95% HLA-mismatched, and 97% received calcineurin-based graft-ver

99 s of acute leukemia, a transplant from a HLA-mismatched donor and from cord blood, older age, and dur

100 his phase 1 and 2 trial, we administered HLA-mismatched anti-CD19 CAR-NK cells derived from cord bloo

101 re were no differences in survival after HLA-mismatched related, HLA-matched unrelated, or mismatched

102 Outcome after HLA-mismatched unrelated donor transplantation is influenced

103 eceptors (TCRs) isolated from allogeneic HLA-mismatched TCR repertoires has, however, been impeded by

104 iral infections underwent an allogeneic, HLA-mismatched HSCT.

105 Allogeneic, HLA-mismatched off-the-shelf third-party donors may offer id

106 rall graft failure risk was higher among HLA-mismatched versus HLA-matched transplants (adjusted haza

107 ear of transplant (P = 0.015), having an HLA-mismatched donor (P < 0.001), and being a male recipient

108 alysis, GF was associated with having an HLA-mismatched donor (P < 0.05) or MUD (P = 0.015) and with

109 risk of sclerosis included the use of an HLA-mismatched donor and a major ABO-mismatched donor.

110 cence (operational tolerance) against an HLA-mismatched graft, allowing them to withdraw all immunosu

111 h risk of GVHD, infection, or both in an HLA-mismatched setting.

112 HLA-matched unrelated donor (344), or an HLA-mismatched unrelated donor (98).

113 ty after receipt of a transplant from an HLA-mismatched unrelated donor.

114 polymorphisms in the unrelated HSCT and HLA-mismatched setting.

115 d unrelated CB (UCB) (57%; P = .031) and HLA-mismatched UD (41%; P = .007).

116 ut significant suppression of completely HLA-mismatched, Ag-induced proliferation.

117 When considering HLA-mismatched transplantation for Hodgkin or non-Hodgkin ly

118 pposed to 79% for MUD grafts and 56% for HLA-mismatched grafts (P = 0.03).

119 isk of rejection over the first year for HLA-mismatched recipients (0.87, P<0.001).

120 n of WT1-specific T cells generated from HLA-mismatched donors should be performed with appropriate p

121 afts from HLA-matched siblings, 13% from HLA-mismatched relatives, 12% from HLA-matched, and 41% from

122 ives, 12% from HLA-matched, and 41% from HLA-mismatched unrelated donors.

123 Simulations using 46 ICPs and 11 fully HLA-mismatched CPs were undertaken using the Australian KPD

124 suggesting that the allograft of Class I HLA-mismatched seropositive donors is inaccessible to CD8+ T

125 -up in a phase IIb tolerance protocol in HLA-mismatched recipients of living donor kidney plus facili

126 sms for this, we compared the ability of HLA-mismatched CB and adult peripheral blood (PB) T cells to

127 matched unrelated donors (MUDs, 66), or HLA-mismatched donors (38).

128 multiple viruses included cord blood or HLA-mismatched HCT, myeloablative conditioning, and acute gr

129 ransplantation using T-cell depletion or HLA-mismatched or umbilical cord donors was also excluded.

130 ny age with a haploidentical relative or HLA-mismatched unrelated donor and patients age 13 years or

131 that the adoptive transfer of partially HLA-mismatched virus-specific CTL is safe despite in vitro r

132 al for control of GVHD in T-cell-replete HLA-mismatched transplantation.

133 ads containing the corresponding donor's HLA-mismatched Ags.

134 ctive T cell repertoire for any specific HLA-mismatched donor-recipient pair.

135 atched set and relapse (P < .001) in the HLA-mismatched cohort.

136 ase, the risk of death was higher in the HLA-mismatched group than in the cord-blood group (hazard ra

137 ociations was lower (hazard ratio in the HLA-mismatched group, 1.28; 95% CI, 0.51 to 3.25; P=0.60; ha

138 d ratios were lower (hazard ratio in the HLA-mismatched group, 1.36; 95% CI, 0.76 to 2.46; P=0.30; ha

139 he cord-blood group (hazard ratio in the HLA-mismatched group, 3.01; 95% CI, 1.22 to 7.38; P=0.02; ha

140 phisms (SNPs) in 2628 patients and their HLA-mismatched unrelated donors to determine whether SNPs ar

141 HIV-1 that persist upon transmission to HLA-mismatched hosts may spread in the population as the epi

142 han 25 x 10(9)/L before transplantation, HLA-mismatched unrelated donor, ASXL1 mutation, and non-CALR

143 Bortezomib-treated HLA-mismatched patients experienced rates of NRM, acute and

144 = 577) as well as to patients undergoing HLA-mismatched allo HCT.

145 ansgenic mice and in patients undergoing HLA-mismatched hematopoietic cell transplantation (HCT), NK

146 was alloantigen-specific expanded using HLA-mismatched immature, mature monocyte-derived dendritic c

147 Here we addressed these questions using HLA-mismatched liver allografts to discriminate the liver-re

148 om two patients were cotransplanted with HLA-mismatched human islets into immunodeficient mice.

149 We treated mice with HLA-mismatched mouse cardiac transplant with atorvastatin an

150 Life-threatening risks associated with HLA-mismatched unrelated donor hematopoietic cell transplant

151 ansplant of minor histocompatibility Ag (HY)-mismatched skin grafts from TORC2(DC-/-) donors into wil

152 D20 antibody, prior to receiving MHC class I-mismatched (K(d) ) skin.

153 ed 1.5 Gy whole body irradiation and class I-mismatched (SLA(gg) ) kidneys from naive pigs with or wi

154 to Mycobacterium tuberculosis in MHC class I-mismatched animals, as well as from Th1-biased dams to T

155 Similarly, whereas MHC class I-mismatched B6.K(d) hearts survived indefinitely and rema

156 rom major histocompatibility complex class I-mismatched donors using flow cytometry and immunohistoch

157 during the maintenance period after class I-mismatched Int-Tx, 5% to 10% myeloid chimerism was found

158 ransplant, group 1 (n = 3) underwent class I-mismatched kidney transplantation; group 2 (n = 3) under

159 oup 2 (n = 3) underwent 2 sequential class I-mismatched kidney transplantations; group 3 (n = 2) unde

160 we attempted to induce tolerance of class I-mismatched kidneys by adoptive transfer of cells and/or

161 miniature swine, which had accepted class I-mismatched kidneys long-term after 12 days of high-dose

162 ted long-term on animals tolerant of class I-mismatched kidneys, with the exception of epidermis, the

163 amino acid differences in single HLA class I-mismatched molecules, the probability of T cell alloreac

164 hanisms are involved in tolerance of class I-mismatched renal allografts in miniature swine treated w

165 underwent bilateral nephrectomy and class I-mismatched renal transplantation with a 12-day course of

166 ansplant arteriosclerosis in an MHC class II-mismatched allograft model.

167 accelerated in KO recipients of MHC class II-mismatched B6.C-H-2(bm12) heart transplants versus wild-

168 contrast, chronic rejection of MHC class II-mismatched bm12 cardiac allografts was accelerated in Fc

169 by passenger CD4 T cells within MHC class II-mismatched bm12 heart grafts provokes antinuclear humora

170 jor antigen-mismatched skin and MHC class II-mismatched cardiac allografts.

171 t not female (HY(-)) recipients using MHC II-mismatched, parent-->F1, and miHAg-mismatched murine bon

172 Results Immune-mismatched stem cell implants demonstrated stronger feru

173 transplantation in rats from immunologically-mismatched inbred strains.

174 e of the composite waveguide at an impedance-mismatched fluidic interface, tunable sound transmission

175 189 days) and a significant expansion of KIR-mismatched NK cells (median, 5,800/mL of blood on day 14

176 e to further investigate the efficacy of KIR-mismatched NK cells in a phase II trial as consolidation

177 antisense oligonucleotides (ASOs): Bcl-x(L)-mismatched control and Bcl-x(L)-specific.

178 fundamentally unavoidable in highly lattice-mismatched epitaxy(9-11).

179 xial semiconductor nanostructures in lattice-mismatched material systems.

180 vely to study stress distribution in lattice-mismatched semiconductor heterostructures.

181 he monolithic integration of largely lattice-mismatched systems by covering a wide range of the misfi

182 ing difficulties in heteroepitaxy of lattice-mismatched semiconductors of desired functionalities but

183 time, conventional heteroepitaxy of lattice-mismatched systems produces dislocations above a critica

184 ovskite single-crystal thin films on lattice-mismatched halide perovskite substrates.

185 is typically achieved via growth on lattice-mismatched substrates.

186 r Ge/Si should be relevant for other lattice-mismatched heterostructure systems, too.

187 ge, owing to the absence of suitable lattice-mismatched epitaxial substrates.

188 xtend the supracrystalline growth to lattice-mismatched binary nanocrystal superlattices, in order to

189 sing the transition to the undesired lattice-mismatched phases.

190 th of epitaxial nanocomposites using lattice-mismatched constituents also enables strain-engineering,

191 und that co-reconstitution with 2 KIR ligand-mismatched compartments did not alter the frequency of K

192 ve killer cell Ig-like receptor (KIR) ligand-mismatched, T cell-depleted, allogeneic transplantation

193 A/H3N2, and further reduced against lineage-mismatched influenza B.

194 17-2018, influenza A(H3N2), H1N1 and lineage-mismatched influenza B/Yamagata cocirculated; VE was sta

195 ia and 27% (95% CI, -21% to 56%) for lineage-mismatched B/Yamagata.

196 s were influenza A(H1N1) and vaccine lineage-mismatched influenza B/Victoria; the VE for fully vaccin

197 sgenic mouse line (Mos-iCsp3) in which a lox-mismatched Cre/lox cassette can be activated to produce

198 in a minor histocompatibility antigen (mHA)-mismatched mouse model.

199 r histocompatibility antigen-mismatched (mHA-mismatched) and fully MHC-mismatched models of bone marr

200 HD in major histocompatibility complex (MHC)-mismatched and MHC-matched BMT following conditioning wi

201 Using major histocompatibility complex (MHC)-mismatched and MHC-matched murine BMT models, we found t

202 al of major histocompatibility complex (MHC)-mismatched cardiac allografts.

203 on of major histocompatibility complex (MHC)-mismatched mixed chimerism reversed autoimmunity and ree

204 from major histocompatibility complex (MHC)-mismatched VIP-knockout (KO) or wild-type donors, and tr

205 full major histocompatibility complex (MHC)-mismatched, multiorgan system model with BO, donor T-cel

206 sociated with an immune response against MHC-mismatched grafted cells.

207 th syngenic MHC-matched and in allogenic MHC-mismatched studies as C57BL/6 (H-2(b)) and BALB/cBy (H-2

208 Using an MHC-mismatched model of acute GVHD, in the present study we

209 cute GVHD models with C57BL/6 donors and MHC-mismatched BALB/c recipients and with C3H.SW donors and

210 e or IFN-gamma(-/-) counterparts in both MHC-mismatched and MHC-matched but minor histocompatibility

211 ve TCRs with endogenous TCRalpha-chains; MHC-mismatched H-2(b) but not matched H-2(g7) mixed chimeris

212 duce high titers of antibody to complete MHC-mismatched heart and renal allografts.

213 nfected with m3KODeltanef than in either MHC-mismatched MCMs infected with m3KODeltanef or MCMs infec

214 rsus-solid tumor (GvT) effects following MHC-mismatched allogeneic bone marrow transplantation (allo-

215 trials of TLI/ATG/alkylator regimens for MHC-mismatched BMT for hemoglobinopathies.

216 ues with two sequential skin grafts from MHC-mismatched donors; four of them were also desensitized w

217 ).BDC2.5 TCD BM cells with BM cells from MHC-mismatched T cell-deficient C57BL/6 mice into lethally i

218 tion; and group 4 (n = 2) underwent full MHC-mismatched heart/kidney transplantation.

219 inite islet allograft survival in a full MHC-mismatched model without the need for any immunosuppress

220 ces long-term allograft survival in full MHC-mismatched models of allogeneic islet and cardiac transp

221 ced CD8(+) Foxp3(+) T cells protect full MHC-mismatched skin allografts.

222 recipients spontaneously accepted fully MHC-mismatched A/J renal allografts, recipients containing d

223 reliably evade immune rejection in fully MHC-mismatched allogeneic recipients and survive long-term w

224 C57BL/6 recipients receiving a fully MHC-mismatched BALB/c heart graft treated with CTLA4Ig + don

225 nts treated with CTLA4-Ig rejected fully MHC-mismatched BALB/c heart transplants, treatment of IL-6-d

226 howed that CC (PEG MG) islets from fully MHC-mismatched Balb/c mice supported long-term (>100 days) s

227 enotoxic conditioning protocol for fully MHC-mismatched bone marrow allotransplantation in mice invol

228 Also, KO recipients of fully MHC-mismatched cardiac allografts are resistant to the graft

229 Tregs led to long-term survival of fully MHC-mismatched cardiac allografts, and prevented development

230 ) but not wild-type mice receiving fully MHC-mismatched cardiac transplants became tolerant and showe

231 Fully MHC-mismatched heart allografts were transplanted into three

232 Aorta transplantation between fully MHC-mismatched mice in association with intravenous LG3 inje

233 ival of cardiac allografts in this fully MHC-mismatched model, it significantly prolonged graft survi

234 en-mismatched (mHA-mismatched) and fully MHC-mismatched models of bone marrow transplantation.

235 ere, we studied TLR signaling in a fully MHC-mismatched, life-sustaining murine model of kidney allog

236 group 3 (n = 2) underwent haploidentical MHC-mismatched heart/kidney transplantation; and group 4 (n

237 lecular targets in vivo was confirmed in MHC-mismatched experimental BMT.

238 c T cells, can be positively selected in MHC-mismatched H-2(b) thymus.

239 ies used high doses of CD4(+) T cells in MHC-mismatched models that caused rapid and lethal GVHD.

240 ffector T cell responses was observed in MHC-mismatched recipients of TORC2(DC-/-) grafts.

241 ular perfusion and tissue oxygenation in MHC-mismatched transplants.

242 /-).BDC2.5 mice into lethally irradiated MHC-mismatched H-2(b) C57BL/6 or MHC-matched congenic B6.H-2

243 , and caused ameliorated GVHD in a major MHC-mismatched model of HCT.

244 zation strategy, we sensitized maximally MHC-mismatched rhesus pairs with two sequential skin transpl

245 In a murine MHC-mismatched BM transplantation model, we observed that IL

246 Despite these observations, using murine MHC-mismatched skin and heart transplant models, donor-deriv

247 tion into ABO-compatible, nonsensitized, MHC-mismatched recipients.

248 Using a murine model of MHC-mismatched cardiac transplantation, we investigated the

249 Using a mouse model of MHC-mismatched heart transplantation, we report markedly pro

250 Therefore, induction of MHC-mismatched mixed chimerism depletes pre-existing and de

251 Induction of MHC-mismatched mixed chimerism results in depleting host-typ

252 ctive transgenic T cells is dependent on MHC-mismatched donor BM-derived APCs but not on donor BM-der

253 erant to 'self' and capable of rejecting MHC-mismatched skin allografts.

254 ney transplantation model that subjected MHC-mismatched BALB/c kidney allografts to cold-ischemia sto

255 Subsequently, MHC-mismatched macaques underwent intraportal allogeneic isl

256 aken together, our studies indicate that MHC-mismatched mixed chimerism can mediate thymic deletion o

257 Our recent studies suggest that MHC-mismatched mixed chimerism mediates negative selection o

258 on, we studied rhesus monkeys undergoing MHC-mismatched islet allotransplants treated with belatacept

259 ived saline (negative control), unsorted MHC-mismatched PBMC (positive control), PBMC enriched with C

260 either mixed or complete chimerism with MHC-mismatched BM transplants prevented T1D in such mice.

261 Induction of mixed chimerism with MHC-mismatched, but not matched, donor BM transplants re-est

262 ng MHC II-mismatched, parent-->F1, and miHAg-mismatched murine bone marrow transplantation models.

263 potential of IFNgammaR(-/-) Tconv in a minor-mismatched GVHD model.

264 histocompatibility complex major- and minor-mismatched murine model significantly delayed the onset

265 at transplant centers give priority to GVH-O-mismatched units over other mismatches and avoid selecti

266 nsgenic BDC2.5-NOD mice with MHC-matched or -mismatched MHC II(-/-) BM transplants failed to induce t

267 ted by CD4+ T cells directed against patient-mismatched HLA-DPB1 molecules on hematopoietic cells and

268 s that use ecologically- and physiologically-mismatched diets over-estimate susceptibility and under-

269 fibrosis progression in this high-risk race-mismatched group need to be investigated.

270 hrough an interface of refractive index (RI)-mismatched substances (i.e., a discrepancy between the R

271 after the first MVA-CMDR boost, the sequence-mismatched DNA-prime MVA-boost vaccine strategy induced

272 conclude that immune responses to "sequence-mismatched" FVIII products are unlikely to contribute ap

273 In 3 of 4 sex-mismatched specimens, tissue XY-karyotyping of the RPM i

274 d endomyocardial biopsy specimens from 7 sex-mismatched (female donor heart to a male recipient) hear

275 iver biopsy samples of 14 patients after sex-mismatched (female-to-male) liver transplantation were i

276 udied the kinetics of LC-chimerism after sex-mismatched allogeneic hematopoietic cell transplantation

277 cute graft-versus-host disease following sex-mismatched HLA-identical bone marrow transplantation.

278 bridization demonstrated rare cells from sex-mismatched donors.

279 airway inflammatory cells isolated from sex-mismatched lung transplant recipients.

280 transplantation of a minor antigen (HY) sex-mismatched heart graft, the lymphatic flow index was sig

281 investigate the origin of hepatocytes in sex-mismatched cases of orthotopic liver transplantation in

282 graft dendritic cells was sought in nine sex-mismatched recipients using XY fluorescence in situ hybr

283 Because clinical data suggest that sex-mismatched H-Y Ags may be important minor histocompatibi

284 rmed from seeded scaffold anastomosed to sex-mismatched natural vessel segments, we demonstrate that

285 Relative to sex-mismatched scores, sex-matched polygenic hazard scores s

286 In addition, we demonstrate using sex-mismatched chimeric hosts that bone marrow is not a sign

287 ts complexes with perfect-matched and single-mismatched complementary DNA molecules were examined by

288 NA distinguishing perfect-matched and single-mismatched target DNA molecules to the best extent, like

289 a high selectivity that discriminates single-mismatched DNA from fully matched target DNA under optim

290 s a new alternative strategy for doping size-mismatched functional atoms into wide band-gap materials

291 arly interstitial fibrosis (r<0.45) for size-mismatched allograft recipients.

292 ed and one was overlooked when using subtype-mismatched pMHC multimer collections.

293 between portal and capsid, across a symmetry-mismatched interface.

294 ates a unique and unusually dynamic symmetry-mismatched vertex that is central to building an infecti

295 americ ClpP surface with the empty, symmetry-mismatched IGL pocket maintained at the seam.

296 tively resolve neighboring pairs of symmetry-mismatched layers of the portal vertex.

297 This work showcases how to resolve symmetry-mismatched elements in a large eukaryotic virus and prov

298 of its N-terminal loops, which the symmetry-mismatched binding of ClpA suffices to induce.

299 ear-atomic in situ structure of the symmetry-mismatched portal vertex from bacteriophage T4.

300 pression by NK cells is required for in vivo-mismatched bone marrow allograft rejection as well as fo